Skip to main content
. Author manuscript; available in PMC: 2011 Jan 15.
Published in final edited form as: Cancer Res. 2010 Jan 12;70(2):532–542. doi: 10.1158/0008-5472.CAN-09-1477

Figure 5. BRCA1 forms a negative regulatory complex with E2F-1 and Rb at the BRCA1 promoter that is disrupted by genotoxic stress.

Figure 5

(A) Co-immuno-precipitation of BRCA, Rb and E2F-1 using antibodies against non-specific IgG, α-Rb and α-BRCA1 antibodies. (B) ChIP-qPCR analysis of Rb enrichment at the indicated positions of the BRCA1 promoter region in untreated Jurkat T cells and cells treated 3 h with 1 µM doxorubicin compared to non-specific control (α-Gal4). (C) α-E2F-1 ChIP-qPCR analysis of E2F-1 enrichment at the indicated positions of the BRCA1 promoter region in untreated Jurkat T cells and cells treated 3 h with 1 µM doxorubicin compared to non-specific control (α-Gal4). (D) Untreated Jurkat cells or cells treated with 1 µM doxorubicin were analyzed by tandem BRCA1/E2F-1 ChIP using combinations of first ChIP with either non-specific antibody (α-Gal4), or α-BRCA1 antibody followed by Re-ChIP of the immunoprecipitated complexes with α-Gal4, α-BRCA1 or α-E2F-1. Mean enrichment and error shown correspond to the average and standard deviation of the mean of at least two independent experiments.